Forcefield Therapeutics
Forcefield Therapeutics is a pioneering biotech company focused on developing best-in-class therapeutics to protect and retain heart function following myocardial infarction (heart attack). Backed by Syncona, the company leverages innovative protein discovery platforms to identify and develop cardioprotective proteins aimed at preventing heart failure and improving patient outcomes.
Industries
Nr. of Employees
small (1-50)
Forcefield Therapeutics
Victoria House, Bloomsbury Square, London, WC1B 4DA
Products
Protein-based cardioprotective therapeutic candidates (preclinical)
Preclinical protein/biologic candidates identified by in vivo secretome screening that preserve cardiomyocyte viability, induce protective autophagy, reduce apoptosis and limit fibrosis when administered after myocardial infarction; intended for short-term acute administration to reduce cardiac damage and progression to heart failure.
Protein-based cardioprotective therapeutic candidates (preclinical)
Preclinical protein/biologic candidates identified by in vivo secretome screening that preserve cardiomyocyte viability, induce protective autophagy, reduce apoptosis and limit fibrosis when administered after myocardial infarction; intended for short-term acute administration to reduce cardiac damage and progression to heart failure.
Services
Granting rights and know-how to external developers to enable AAV gene therapy programs based on discovered cardiac protein genes.
Partner-based execution of discovery validation, preclinical development and CMC activities using a virtual R&D model.
Lead candidate selection, mechanism-of-action studies and preclinical efficacy testing intended to support first-in-human studies.
Granting rights and know-how to external developers to enable AAV gene therapy programs based on discovered cardiac protein genes.
Partner-based execution of discovery validation, preclinical development and CMC activities using a virtual R&D model.
Lead candidate selection, mechanism-of-action studies and preclinical efficacy testing intended to support first-in-human studies.
Expertise Areas
- Cardioprotective therapeutic discovery
- In vivo functional screening and selection
- Protein biotherapeutics development
- AAV-based gene product discovery and translational use
Key Technologies
- AAV-based in vivo secretome screening
- Gene-agnostic functional selection in animal models
- Protein/biotherapeutic candidate development
- Rodent myocardial infarction models
News & Updates
John Tsai MD has been appointed as CEO to lead the company's efforts in developing novel therapeutics for heart attack treatment.
Forcefield has entered into an agreement with Freeline to develop and commercialize AAV gene therapies using cardiac protein targets.
Preclinical data on three proteins identified by FunSel platform show potential to restore heart function after MI.
Discovery of three proteins that can be administered immediately after MI to prevent heart failure, supported by studies at King’s College London.
Article discussing Forcefield's mission to develop therapies to prevent heart cell death post-MI.
John Tsai MD has been appointed as CEO to lead the company's efforts in developing novel therapeutics for heart attack treatment.
Forcefield has entered into an agreement with Freeline to develop and commercialize AAV gene therapies using cardiac protein targets.
Preclinical data on three proteins identified by FunSel platform show potential to restore heart function after MI.
Discovery of three proteins that can be administered immediately after MI to prevent heart failure, supported by studies at King’s College London.
Article discussing Forcefield's mission to develop therapies to prevent heart cell death post-MI.